基于线粒体功能障碍与代谢重编程的脓毒症相关急性肾损伤治疗研究进展
该综述聚焦脓毒症相关急性肾损伤(SA-AKI)的两大核心病理机制——线粒体功能障碍与代谢重编程。肾脏因线粒体密度高、能量需求大而对线粒体功能障碍尤为敏感;脓毒症时肾细胞代谢模式由氧化磷酸化转向有氧糖酵解并伴脂肪酸氧化抑制,初始为适应性保护反应,但持续代谢失衡导致脂质蓄积和纤维化,进展为慢性肾脏病。两机制相互作用共同促成SA-AKI发生与进展。文章系统回顾了靶向这两大机制的治疗策略研究进展,阐述线粒体保护剂和代谢调节剂的潜在应用价值、作用机制、体外与体内实验证据及临床转化前景,并总结当前研究瓶颈。
要点
- SA-AKI是脓毒症最常见并发症之一,发生率和病死率高,目前临床仍以支持治疗为主,缺乏特异性靶向药物。
- 肾脏线粒体密度高、能量需求大,对线粒体功能障碍特别敏感,是SA-AKI机制研究的关键靶点。
- 脓毒症时肾细胞代谢由氧化磷酸化转向有氧糖酵解并抑制脂肪酸氧化,持续失衡可致脂质蓄积、纤维化并进展为慢性肾脏病。
- 线粒体保护剂和代谢调节剂是当前SA-AKI靶向治疗的研究方向,但综述仅阐述其潜在应用价值与临床转化前景,未给出临床推荐剂量或疗效结论。
- 文章总结了当前研究瓶颈并展望未来方向,旨在为SA-AKI精准靶向治疗提供理论依据和新研究思路。
适用人群与场景
- 脓毒症患者中发生急性肾损伤(SA-AKI)的人群;原文未给出具体纳入/排除标准或适用场景(急诊、ICU或院前)的限定。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体处置流程或药物剂量;仅指出目前临床以支持治疗为主,缺乏特异性靶向药物。
- 综述讨论了线粒体保护剂和代谢调节剂的潜在应用价值、作用机制及体外/体内实验证据,但未给出临床可用的剂量、途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 本文为综述,系统回顾了基于线粒体功能障碍与代谢重编程的SA-AKI靶向治疗策略研究进展,包括线粒体保护剂和代谢调节剂的机制、体外与体内实验证据及临床转化前景;原文未报告具体研究样本量、效应量或统计学结果。
证据类型、等级与局限
- 证据类型为综述;原文未给出证据等级或推荐强度。
- 局限:文中所述线粒体保护剂与代谢调节剂多基于体外和体内实验证据,临床转化前景尚待验证,缺乏临床靶向药物证据。
对床旁实践的改变
- 本文不改变当前SA-AKI以支持治疗为主的临床实践,未提供可直接用于床旁的靶向药物方案。
- 提示线粒体功能障碍与代谢重编程是SA-AKI潜在治疗靶点,但相关药物尚处研究阶段,临床使用需等待进一步转化验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis-associated acute kidney injury (SA-AKI) is one of the most common complications of sepsis, characterized by high incidence and mortality. Currently, supportive treatment remains the main approach in clinical practice, lacking specific targeted drugs. Mitochondrial dysfunction and metabolic reprogramming play significant roles in the pathophysiological process of SA-AKI. The kidneys, with their high mitochondrial density and high energy demand, are particularly sensitive to mitochondrial dysfunction. Metabolic reprogramming is another important mechanism for the onset of SA-AKI. When sepsis occurs, the metabolic patterns of kidney cells undergo significant changes, initially shifting from oxidative phosphorylation (OXPHOS) to aerobic glycolysis metabolism, accompanied by inhibition of fatty acid oxidation (FAO). The initial intention is an adaptive protective response of the cells, but persistent metabolic imbalance leads to lipid accumulation and fibrosis, progressing to chronic kidney disease. The two mechanisms interact with each other, jointly causing the occurrence and progression of SA-AKI. This article focuses on these two core mechanisms, systematically reviews the research progress of targeted treatment strategies of SA-AKI, elaborates on the potential application value of mitochondrial protectants and metabolic regulators, deeply analyzes the mechanism of action, in vitro and in vivo experimental evidence, and clinical translation prospects of various drugs, summarizes the current research bottlenecks and looks forward to future development directions, aiming to provide theoretical basis and new research ideas for precise targeted treatment of SA-AKI.
参考来源
- Zhao S, Huangfu W, Zhou L, et al. [Research advances on the treatment of sepsis-associated acute kidney injury based on mitochondrial dysfunction and metabolic reprogramming]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42563684. doi:10.3760/cma.j.cn121430-20260224-00097
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。